IQVIA Holdings Inc. (NYSE:IQV) Shares Acquired by Wedmont Private Capital

Wedmont Private Capital boosted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 9.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,042 shares of the medical research company’s stock after purchasing an additional 178 shares during the period. Wedmont Private Capital’s holdings in IQVIA were worth $460,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Versant Capital Management Inc increased its stake in IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after buying an additional 110 shares during the period. Opal Wealth Advisors LLC acquired a new position in IQVIA in the 2nd quarter valued at approximately $27,000. Park Place Capital Corp bought a new stake in IQVIA in the third quarter worth approximately $28,000. Itau Unibanco Holding S.A. bought a new stake in IQVIA in the second quarter worth approximately $29,000. Finally, Rise Advisors LLC bought a new stake in IQVIA in the first quarter worth approximately $31,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have weighed in on IQV shares. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a report on Friday, September 27th. Robert W. Baird increased their price objective on shares of IQVIA from $251.00 to $256.00 and gave the company a “neutral” rating in a research note on Friday, September 20th. Royal Bank of Canada assumed coverage on shares of IQVIA in a research report on Wednesday, September 4th. They set an “outperform” rating and a $275.00 target price for the company. Truist Financial raised their price objective on shares of IQVIA from $292.00 to $300.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Finally, UBS Group raised their price objective on shares of IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Five research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and an average price target of $269.36.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.60% of the company’s stock.

IQVIA Price Performance

Shares of IQV opened at $229.24 on Friday. The firm has a market capitalization of $41.79 billion, a PE ratio of 29.77, a PEG ratio of 2.18 and a beta of 1.49. The company’s 50-day moving average is $239.41 and its 200-day moving average is $231.99. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, beating the consensus estimate of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The business had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.79 billion. During the same period in the prior year, the company posted $2.22 earnings per share. IQVIA’s revenue was up 2.3% compared to the same quarter last year. Equities analysts forecast that IQVIA Holdings Inc. will post 10.25 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.